Terumo (OTCMKTS:TRUMY – Get Free Report) released its quarterly earnings data on Friday. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.13, Zacks reports. Terumo had a net margin of 12.09% and a return on equity of 9.17%. The firm had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion.
Terumo Stock Performance
OTCMKTS TRUMY opened at $15.85 on Friday. The stock has a market capitalization of $23.38 billion, a PE ratio of 25.98 and a beta of 0.68. The business has a 50 day simple moving average of $14.00 and a two-hundred day simple moving average of $13.56. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.59 and a quick ratio of 0.97. Terumo has a 1-year low of $12.08 and a 1-year high of $19.60.
Analyst Upgrades and Downgrades
Separately, Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Terumo currently has an average rating of “Buy”.
About Terumo
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
Featured Stories
- Five stocks we like better than Terumo
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
